Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients? (Inapprop)
|ClinicalTrials.gov Identifier: NCT01605370|
Recruitment Status : Terminated (Difficulty in identifying subjects satisfying the inclusion criteria.)
First Posted : May 24, 2012
Results First Posted : May 7, 2014
Last Update Posted : May 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Nebivolol Drug: Metoprolol succinate||Phase 4|
In response to chronic pressure overload by arterial hypertension, the cardiac left ventricle undergoes hypertrophy, that is, increases its wall thickness and, therefore, its mass, to sustain the elevated workload. Such anatomical remodeling can be considered adaptive or appropriate. However, in a considerable number of patients with arterial hypertension, the increase in the left ventricular mass is excessive and, thus, inappropriate.
Ventricular mass is inappropriate when its amount surpasses the physical need of the ventricle to sustain the elevated workload. Therefore, ventricular mass can be inappropriate even in patients without arterial hypertension or without hypertrophy identified by echocardiography (echo). We can mathematically predict an appropriate amount of mass and observe the actual mass in individual patients based on ventricular workload and wall thickness, respectively, noninvasively evaluated by echo. By comparing the observed ventricular mass to the predicted one, we determine whether its amount is inappropriate. It follows that by therapeutically normalizing blood pressure in hypertension and thus eliminating the elevated workload, then any ventricular hypertrophy represents an inappropriate mass.
Inappropriate ventricular mass is proven to have a detrimental effect on long-term cardiovascular event-free survival, and ventricular hypertrophy is increasingly recognized as a potent risk factor of cardiovascular morbidity and mortality, and all-cause mortality. Ventricular performance is altered in hypertension with inappropriate mass, but this alteration can be subtle enough to escape detection using current echocardiography measures. Hence, patients with hypertension, who have inappropriate left ventricular mass, need to be specifically identified by analysis of the predicted and observed ventricular mass, and the therapeutic goal must include management of elevated blood pressure as well as reversal of the excessive ventricular mass.
In this double-blind prospective study, patients with hypertension and inappropriate ventricular mass will be randomized to therapy with nebivolol or metoprolol to find out whether nebivolol could reverse inappropriate left ventricular mass, thus providing a benefit beyond what is achieved by mere blood pressure reduction alone. If confirmed, this will represent a significant ancillary ability of nebivolol and be a key step towards therapy of inappropriate ventricular mass, which is a so far unmanaged cardiovascular risk and a poor event-free prognostic factor.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
Nebivolol 2.5 mg once daily
Other Name: Bystolic
Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
Drug: Metoprolol succinate
Metoprolol succinate 50 mg once daily
Other Name: Toprol XL
- Change in Inappropriate Left Ventricular Mass (LVM) [ Time Frame: baseline, 6 months ]LVM will be measured by echocardiography exam. LVM is inappropriate when observed LVM (oLVM) exceeds predicted LVM (pLVM) by more than 28%, that is, 100×(oLVM/pLVM) >128%.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01605370
|United States, Arizona|
|Mayo Clinic Arizona|
|Scottsdale, Arizona, United States, 85259|
|Principal Investigator:||Marek Belohlavek, MD, PhD||Mayo Clinic|